Aclaris Therapeutics, Inc. (ACRS) vs Sagimet Biosciences Inc. (SGMT)

Aclaris Therapeutics, Inc. and Sagimet Biosciences Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Sagimet Biosciences Inc. are of similar size ($589.0M and $561.1M). Sagimet Biosciences Inc. has the higher net margin (0.00% vs −921.5%) and the lower return on invested capital (−205.2% vs −163.4%). Across the 13 metrics below, Sagimet Biosciences Inc. leads on 7 and Aclaris Therapeutics, Inc. on 6.

Valuation

Metric ACRS SGMT Biotechnology median
P/E n/m n/m 7.88
P/S 89.44 n/m 11.47
P/B 5.90 1.92 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 78.52 n/m 10.73
Earnings yield (11.26%) (13.85%) (28.84%)
Free cash flow yield (8.46%) (8.50%) (23.03%)

Profitability

Metric ACRS SGMT Biotechnology median
Gross margin 12.90% 0.00% 65.16%
Operating margin (1,050.16%) 0.00% 0.00%
Net margin (921.50%) 0.00% 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) (24.37%) (57.72%)
Return on assets (41.07%) (23.49%) (49.22%)
Return on invested capital (163.35%) (205.24%) 0.00%

Growth

Metric ACRS SGMT Biotechnology median
Revenue growth (TTM) (51.04%) — 5.64%
EPS growth (last fiscal year) 69.01% (8.97%) —
Revenue growth, 5-year CAGR 3.84% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS SGMT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 45.02 4.73
Net debt to EBITDA 1.20 1.98 0.96

Dividend

Metric ACRS SGMT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ACRS SGMT Biotechnology median
Market cap 588.97m 561.10m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack